RAPT Therapeutics IncNASDAQ:RAPT
- LAST PRICE4.1150
- TODAY'S CHANGE (%)-0.0650 (-1.5550%)
- Bid / Lots4.1100/ 4
- Ask / Lots4.1200/ 3
- Open / Previous Close4.2200 / 4.1800
- Day Range
- 52 Week Range
- Volume234,929
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RAPT |
|---|---|---|
| 09:32 ET | 3343 | 4.25 |
| 09:34 ET | 3505 | 4.33 |
| 09:36 ET | 1929 | 4.21 |
| 09:38 ET | 824 | 4.2185 |
| 09:39 ET | 100 | 4.18 |
| 09:43 ET | 824 | 4.2126 |
| 09:45 ET | 100 | 4.16 |
| 09:48 ET | 1175 | 4.19 |
| 09:52 ET | 1847 | 4.2025 |
| 09:54 ET | 6838 | 4.2 |
| 09:56 ET | 200 | 4.21 |
| 09:57 ET | 485 | 4.195 |
| 09:59 ET | 590 | 4.1985 |
| 10:01 ET | 300 | 4.18 |
| 10:03 ET | 300 | 4.185 |
| 10:06 ET | 296 | 4.185 |
| 10:08 ET | 1148 | 4.17 |
| 10:10 ET | 100 | 4.16 |
| 10:12 ET | 1360 | 4.18 |
| 10:14 ET | 537 | 4.18 |
| 10:17 ET | 2047 | 4.2 |
| 10:19 ET | 100 | 4.2 |
| 10:21 ET | 100 | 4.2 |
| 10:26 ET | 1183 | 4.18 |
| 10:28 ET | 3701 | 4.15 |
| 10:30 ET | 1201 | 4.16 |
| 10:32 ET | 2749 | 4.17 |
| 10:33 ET | 1137 | 4.18 |
| 10:35 ET | 7648 | 4.205 |
| 10:37 ET | 800 | 4.21 |
| 10:39 ET | 2553 | 4.24 |
| 10:42 ET | 700 | 4.245 |
| 10:44 ET | 3407 | 4.27 |
| 10:46 ET | 800 | 4.27 |
| 10:48 ET | 900 | 4.29 |
| 10:50 ET | 400 | 4.29 |
| 10:51 ET | 600 | 4.3 |
| 10:53 ET | 1444 | 4.28 |
| 10:55 ET | 858 | 4.3 |
| 10:57 ET | 900 | 4.3 |
| 11:00 ET | 5563 | 4.29 |
| 11:02 ET | 1991 | 4.31 |
| 11:04 ET | 850 | 4.31 |
| 11:06 ET | 500 | 4.32 |
| 11:08 ET | 6528 | 4.32 |
| 11:09 ET | 1598 | 4.33 |
| 11:11 ET | 1700 | 4.325 |
| 11:13 ET | 931 | 4.34 |
| 11:15 ET | 500 | 4.34 |
| 11:18 ET | 1750 | 4.34 |
| 11:20 ET | 7667 | 4.37 |
| 11:22 ET | 3087 | 4.37 |
| 11:24 ET | 2789 | 4.37 |
| 11:26 ET | 150 | 4.37 |
| 11:27 ET | 750 | 4.37 |
| 11:29 ET | 700 | 4.37 |
| 11:31 ET | 1069 | 4.39 |
| 11:33 ET | 2424 | 4.37 |
| 11:38 ET | 1347 | 4.35 |
| 11:40 ET | 1118 | 4.3316 |
| 11:42 ET | 1630 | 4.34 |
| 11:44 ET | 300 | 4.35 |
| 11:45 ET | 300 | 4.34 |
| 11:47 ET | 650 | 4.35 |
| 11:49 ET | 3459 | 4.33 |
| 11:54 ET | 1108 | 4.34 |
| 11:56 ET | 300 | 4.34 |
| 11:58 ET | 100 | 4.34 |
| 12:00 ET | 600 | 4.33 |
| 12:02 ET | 776 | 4.31 |
| 12:03 ET | 906 | 4.3184 |
| 12:05 ET | 300 | 4.31 |
| 12:07 ET | 2912 | 4.31 |
| 12:09 ET | 2428 | 4.3 |
| 12:12 ET | 300 | 4.3 |
| 12:14 ET | 1450 | 4.3 |
| 12:18 ET | 200 | 4.3 |
| 12:20 ET | 697 | 4.285 |
| 12:21 ET | 254 | 4.28 |
| 12:23 ET | 700 | 4.24 |
| 12:25 ET | 500 | 4.24 |
| 12:27 ET | 4652 | 4.26 |
| 12:30 ET | 295 | 4.24 |
| 12:32 ET | 200 | 4.23 |
| 12:34 ET | 222 | 4.21 |
| 12:36 ET | 1155 | 4.21 |
| 12:38 ET | 200 | 4.2306 |
| 12:41 ET | 251 | 4.22 |
| 12:43 ET | 200 | 4.21 |
| 12:45 ET | 300 | 4.21 |
| 12:48 ET | 100 | 4.21 |
| 12:50 ET | 3298 | 4.19 |
| 12:52 ET | 784 | 4.19 |
| 12:54 ET | 200 | 4.19 |
| 12:56 ET | 200 | 4.18 |
| 12:57 ET | 200 | 4.18 |
| 12:59 ET | 200 | 4.19 |
| 01:01 ET | 1100 | 4.19 |
| 01:03 ET | 4304 | 4.18 |
| 01:06 ET | 700 | 4.15 |
| 01:08 ET | 2423 | 4.17 |
| 01:12 ET | 200 | 4.18 |
| 01:14 ET | 500 | 4.18 |
| 01:15 ET | 945 | 4.17 |
| 01:17 ET | 425 | 4.16 |
| 01:19 ET | 1005 | 4.1762 |
| 01:24 ET | 200 | 4.15 |
| 01:26 ET | 500 | 4.15 |
| 01:28 ET | 551 | 4.15 |
| 01:30 ET | 430 | 4.16 |
| 01:32 ET | 1200 | 4.145 |
| 01:33 ET | 300 | 4.1593 |
| 01:35 ET | 331 | 4.145 |
| 01:39 ET | 1400 | 4.17 |
| 01:42 ET | 200 | 4.17 |
| 01:44 ET | 300 | 4.17 |
| 01:46 ET | 1720 | 4.1615 |
| 01:48 ET | 1300 | 4.15 |
| 01:50 ET | 300 | 4.15 |
| 01:51 ET | 200 | 4.15 |
| 01:53 ET | 100 | 4.15 |
| 01:55 ET | 100 | 4.145 |
| 01:57 ET | 200 | 4.15 |
| 02:00 ET | 1350 | 4.15 |
| 02:02 ET | 3624 | 4.16 |
| 02:04 ET | 509 | 4.16 |
| 02:06 ET | 200 | 4.16 |
| 02:08 ET | 2166 | 4.17 |
| 02:09 ET | 3500 | 4.174 |
| 02:13 ET | 200 | 4.17 |
| 02:15 ET | 200 | 4.17 |
| 02:18 ET | 100 | 4.17 |
| 02:20 ET | 200 | 4.16 |
| 02:22 ET | 200 | 4.17 |
| 02:24 ET | 1643 | 4.14 |
| 02:26 ET | 883 | 4.15 |
| 02:27 ET | 200 | 4.14 |
| 02:29 ET | 500 | 4.13 |
| 02:31 ET | 842 | 4.139 |
| 02:33 ET | 800 | 4.12 |
| 02:38 ET | 500 | 4.13 |
| 02:40 ET | 684 | 4.11 |
| 02:42 ET | 1500 | 4.12 |
| 02:44 ET | 2260 | 4.12 |
| 02:45 ET | 200 | 4.11 |
| 02:47 ET | 450 | 4.11 |
| 02:49 ET | 1100 | 4.1 |
| 02:51 ET | 1418 | 4.11 |
| 02:54 ET | 100 | 4.11 |
| 02:56 ET | 100 | 4.1 |
| 02:58 ET | 600 | 4.11 |
| 03:03 ET | 978 | 4.1097 |
| 03:07 ET | 2625 | 4.115 |
| 03:09 ET | 2277 | 4.115 |
May 14, 2024
DJ Rapt Therapeutics Cut to Peer Perform From Outperform by Wolfe Research, from 8:11AM ET on Tuesday May 14, 2024 by Dow Jones
8:11AM ET on Tuesday May 14, 2024 by Dow Jones
May 10, 2024
DJ Rapt Therapeutics Cut to Equal-Weight From Overweight by Barclays, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow JonesDJ Rapt Therapeutics Cut to Neutral From Buy by Guggenheim, from 6:39AM ET on Friday May 10, 2024 by Dow Jones
6:39AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm, from 3:07PM ET on Thursday May 09, 2024 by Dow Jones
3:07PM ET on Thursday May 09, 2024 by Dow JonesDJ RAPT Therapeutics Shares Hit 52-Week Low After Trials Closed, from 12:49PM ET on Thursday May 09, 2024 by Dow Jones
12:49PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RAPT Therapeutics Inc | 145.5M | -1.3x | --- |
Rezolute Inc | 142.9M | -3.2x | --- |
Context Therapeutics Inc | 150.0M | -1.6x | --- |
Gossamer Bio Inc | 140.2M | -0.6x | --- |
X4 Pharmaceuticals Inc | 151.7M | -1.3x | --- |
Vigil Neuroscience Inc | 136.4M | -1.6x | --- |
Company Information
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Contact Information
- Headquarters
- 561 Eccles AveSOUTH SAN FRANCISCO, CA, United States 94080-1906
- Phone
- 650-489-9000
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- William Rieflin
- President, Chief Executive Officer, Director
- Brian Wong
- Chief Financial Officer
- Rodney Young
- Chief Scientific Officer
- Dirk Brockstedt
- Chief Medical Officer
- William Ho
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $145.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.25 |
EPS | $-3.07 |
Book Value | $4.27 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
